Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of DYN101 in Patients ≥ 16 Years of Age With Centronuclear Myopathies Caused by Mutations in DNM2 or MTM1.

NCT04033159 is registered in ClinicalTrials.gov with Dynacure as lead sponsor.

NCT NCT04033159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04033159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of DYN101 in Patients ≥ 16 Years of Age With Centronuclear Myopathies Caused by Mutations in DNM2 or MTM1.
Lead sponsor
Dynacure
Phase
Phase 1/2
Overall status
Terminated
Start date
January 9, 2020
Completion date
June 22, 2022
Enrollment
14 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

centronuclear myopathy